Gilead has gotten a new HIV preventive treatment, Yeztugo, approved, which consists of two injections a year, promising more effective prevention.
Lara Maior
Current Affairs
Foto Gilead Pharma
Always see our news on Google
Yeztugo, a drug developed by Gilead, has been authorized in the United States as a preventive treatment against HIV. It requires only two injections a year, unlike current treatments that require daily pills. While the treatment could revolutionize the fight against the AIDS epidemic, cost remains a crucial issue, with an estimated annual price tag of about $25,000. UNAIDS director Winnie Byanyima emphasized the importance of making the drug affordable to have a real impact in the fight against AIDS.
Sources
Tratament promiţător împotriva HIV-SIDA. Producătorii promit prețuri accesibil
Statele Unite autorizează un nou tratament preventiv, foarte promiţător, împotriva HIV, virusul care cauzează SIDA
FDA approves first twice-yearly injection that prevents HIV infection
US approves promising preventive HIV treatment
Groundbreaking twice-a-year HIV drug that could stop transmission approved
Latest News
19:25
The first leader from PNL to react after the Fitch report: The measures are going in the right direction.
19:05
The United States embassies in the Middle East are issuing security alerts and recommending that American citizens leave the region.
19:00
A serious accident occurred on DN 1, Cluj County, involving a motorcycle and a truck.
18:50
The wildfire in Reșița has reignited, and additional forces have been mobilized to extinguish it, including a helicopter.
18:40
A lottery winner from Padova who became a millionaire in 2019 is at the center of a post-mortem legal dispute.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
